Recent Comments

Comment RSS

Restless Legs Syndrome News and Research RSS Feed - Restless Legs Syndrome News and Research

Restless legs syndrome (RLS) is a neurological disorder characterized by unpleasant sensations in the legs and an uncontrollable urge to move when at rest in an effort to relieve these feelings. RLS sensations are often described by people as burning, creeping, tugging, or like insects crawling inside the legs. Often called paresthesias (abnormal sensations) or dysesthesias (unpleasant abnormal sensations), the sensations range in severity from uncomfortable to irritating to painful.

The most distinctive or unusual aspect of the condition is that lying down and trying to relax activates the symptoms. As a result, most people with RLS have difficulty falling asleep and staying asleep. Left untreated, the condition causes exhaustion and daytime fatigue. Many people with RLS report that their job, personal relations, and activities of daily living are strongly affected as a result of their exhaustion. They are often unable to concentrate, have impaired memory, or fail to accomplish daily tasks.

Astellas Pharma and XenoPort submit NDA in Japan for PMDA approval

19. November 2009 07:06
Astellas Pharma Inc. and XenoPort, Inc. today announced that a new drug application (NDA) has been filed with the Pharmaceuticals and Medical Device Agency (PMDA) in Japan for ASP8825 (gabapentin enacarbil), also known as XP13512, as a potential treatment for restless legs syndrome (RLS). [More]

Assessing the neurology market and its major players

17. November 2009 04:13
Research and Markets (http://www.researchandmarkets.com/research/63cb3f/dealmaking_and_ind) has announced the addition of Decision Resources, Inc.'s new report "Dealmaking and Industry Outlook: Neurological Disease" to their offering. [More]

Children with autism may have lower quality handwriting, says study

9. November 2009 23:49
Children with autism may have lower quality handwriting and trouble forming letters compared to children without autism, according to a study published in the November 10, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology. [More]

FDA extends review date of New Drug Application for GSK1838262/XP13512

7. November 2009 01:31
GlaxoSmithKline and XenoPort, Inc. (Nasdaq: XNPT) today announced that the U.S. Food and Drug Administration (FDA) has extended the original Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) for GSK1838262/XP13512 (gabapentin enacarbil) to February 9, 2010. The original PDUFA date for this NDA review was November 9, 2009. [More]

Neurogen announces financial results for the third quarter of 2009

6. November 2009 07:33
Neurogen Corporation, a drug development company historically focused on drugs for psychiatric and neurological disorders, today announced financial and operating results for the quarter ended September 30, 2009. [More]

Posted in: Business / Finance

Tags: , ,

Caucasian women may suffer from RLS up to four times more than African-American women

3. November 2009 06:57
New research shows that Caucasian women may suffer from restless legs syndrome (RLS), a sleep disorder characterized by the strong urge to move the legs, up to four times more than African-American women. The study, presented at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP), found that, overall, non-African-American (NAA) patients experienced RLS four times more often than African-Americans (AA). [More]

Posted in: Medical Condition News

Tags: , , , , , ,

Study: High protein levels are associated with heart attack and not stroke

26. October 2009 00:52
People with high levels of a protein called C-reactive protein (CRP), a marker for inflammation in the blood, may be at higher risk for heart attack and death but not stroke, according to a study published in the October 20, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology. [More]

GSK reports positive Phase II results from trial evaluating GSK1838262 for post-herpetic neuralgia

5. October 2009 07:08
GlaxoSmithKline and XenoPort, Inc. today announced top-line results from a Phase II clinical trial evaluating GSK1838262/XP13512 (gabapentin enacarbil) in adult patients with neuropathic pain associated with post-herpetic neuralgia (PHN) who have had a history of inadequate response to gabapentin doses of 1800 mg/day or higher. [More]

Results from Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 announced

17. September 2009 07:02
GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) today announced top-line results from a Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 (gabapentin enacarbil) for neuropathic pain associated with post-herpetic neuralgia (PHN) in adults. [More]

Gabapentin improves sleep quality in menopausal women

9. September 2009 03:59
Gabapentin, a drug initially used to treat seizures, improves sleep quality in menopausal women with hot flashes, University of Rochester Medical Center researchers report online and in the September issue of the Journal of Women's Health. [More]

LTS LOHMANN Therapie-Systeme celebrates 25th anniversary

1. September 2009 05:41
LTS LOHMANN Therapie-Systeme AG, the leading developer and manufacturer of transdermal, topical and oral systems with facilities in Andernach, Germany and West Caldwell, New Jersey, celebrates its 25th anniversary. [More]

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

25. August 2009 01:58
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Neurogen Corporation (NASDAQ:NRGN) announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted Contingent Value Rights (“CVRs”) under four CVR agreements. [More]

Pregabalin shows potential for restless legs syndrome - improves sleep

29. April 2009 23:28
A drug widely used to treat seizures and anxiety appears to be an effective treatment for restless legs syndrome (RLS) and helps people with the disorder get a better night's sleep, according to a study that will be presented as part of the Late-breaking Science Program at the American Academy of Neurology's 61st Annual Meeting in Seattle. [More]

Posted in: Drug Trial News

Tags: , , , , , ,

Dopamine agonists trigger destructive behaviors

9. April 2009 13:49
A new study conducted at Mayo Clinic reports that one in six patients receiving therapeutic doses of certain drugs for Parkinson's disease develops new-onset, potentially destructive behaviors, notably compulsive gambling or hypersexuality. [More]

Posted in: Medical Research News

Tags: , , , ,

Obesity and overweight linked to greater risk of restless legs syndrome

6. April 2009 21:21
A new study shows both obesity and a large belly appear to increase the risk of developing restless legs syndrome (RLS), a common sleep disorder characterized by an irresistible urge to move your legs. [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.